<?xml version='1.0' encoding='utf-8'?>
<document id="31044521"><sentence text="Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach."><entity charOffset="53-66" id="DDI-PubMed.31044521.s1.e0" text="Acalabrutinib" /></sentence><sentence text="Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor"><entity charOffset="0-13" id="DDI-PubMed.31044521.s2.e0" text="Acalabrutinib" /><entity charOffset="44-52" id="DDI-PubMed.31044521.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.31044521.s2.e0" e2="DDI-PubMed.31044521.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31044521.s2.e0" e2="DDI-PubMed.31044521.s2.e1" /></sentence><sentence text=" A physiologically-based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP-5862 to predict potential drug-drug interactions (DDIs)" /><sentence text=" The model indicated acalabrutinib would not perpetrate a CYP2C8 or CYP3A DDI with the sensitive CYP substrates rosiglitazone or midazolam, respectively"><entity charOffset="112-125" id="DDI-PubMed.31044521.s4.e0" text="rosiglitazone" /><entity charOffset="129-138" id="DDI-PubMed.31044521.s4.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.31044521.s4.e0" e2="DDI-PubMed.31044521.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31044521.s4.e0" e2="DDI-PubMed.31044521.s4.e1" /></sentence><sentence text=" The model reasonably predicted clinically observed acalabrutinib DDI with the CYP3A perpetrators itraconazole (4"><entity charOffset="98-110" id="DDI-PubMed.31044521.s5.e0" text="itraconazole" /></sentence><sentence text="80-fold vs" /><sentence text=" 5" /><sentence text="21-fold observed) and rifampicin (0"><entity charOffset="22-32" id="DDI-PubMed.31044521.s8.e0" text="rifampicin" /></sentence><sentence text="21-fold vs" /><sentence text=" 0" /><sentence text="23-fold observed)" /><sentence text=" An increase of two to threefold acalabrutinib area under the curve was predicted for coadministration with moderate CYP3A inhibitors" /><sentence text=" When both the parent drug and active metabolite (total active components) were considered, the magnitude of the CYP3A DDI was much less significant" /><sentence text=" PBPK dosing recommendations for DDIs should consider the magnitude of the parent drug excursion, relative to safe parent drug exposures, along with the excursion of total active components to best enable safe and adequate pharmacodynamic coverage" /><sentence text="" /></document>